Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy

Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.

Gene Editing

Image Credit: Horizon Discovery

Horizon’s OncoSpan range now includes formalin-fixed, paraffin-embedded (FFPE) and cell-free DNA (cfDNA) formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its well-established genomic DNA (gDNA) format.

Its cfDNA format offers one of the largest number of variants and genes, over 380 and 152 respectively, of any characterized reference standard to help standardize liquid biopsy testing.

These cell-line derived reference standards closely mimic patient samples and offer an unlimited and reproducible resource to help ensure consistency during the establishment and validation of diagnostic assays.

All three formats are delivered with batch-specific, next-generation sequencing (NGS) data, orthogonally validated by ddPCR, to allow researchers to further validate their analysis pipeline.

Horizon offers a range of premium reference standards for various molecular platforms including NGS and digital PCR. By extending our OncoSpan portfolio to include these additional sample formats, we are now able to provide more researchers working at the forefront of molecular diagnostics, with the reagents needed to suit their specific workflows. These cell-line derived standards offer significant benefits over less-commutable synthetic standards, meaning researchers can rely on our reference standards to deliver consistent results and have confidence in the performance of their diagnostic assays.”

Paul Brooks, Head of Business Operations, Horizon Discovery

For further information about Horizon’s OncoSpan reference standards, please visit: https://horizondiscovery.com/en/reference-standards/oncospan

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Revvity. (2024, March 27). Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy. News-Medical. Retrieved on December 04, 2024 from https://www.news-medical.net/news/20200429/Horizon-Discovery-extends-coverage-of-OncoSpan-reference-standards-to-FFPE-and-Liquid-Biopsy.aspx.

  • MLA

    Revvity. "Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy". News-Medical. 04 December 2024. <https://www.news-medical.net/news/20200429/Horizon-Discovery-extends-coverage-of-OncoSpan-reference-standards-to-FFPE-and-Liquid-Biopsy.aspx>.

  • Chicago

    Revvity. "Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy". News-Medical. https://www.news-medical.net/news/20200429/Horizon-Discovery-extends-coverage-of-OncoSpan-reference-standards-to-FFPE-and-Liquid-Biopsy.aspx. (accessed December 04, 2024).

  • Harvard

    Revvity. 2024. Horizon Discovery extends coverage of OncoSpan reference standards to FFPE and Liquid Biopsy. News-Medical, viewed 04 December 2024, https://www.news-medical.net/news/20200429/Horizon-Discovery-extends-coverage-of-OncoSpan-reference-standards-to-FFPE-and-Liquid-Biopsy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions